



### Editor

Tracy Crooks

Reckitt Benckiser Healthcare International Ltd  
email: [tracy.crooks@reckittbenckiser.com](mailto:tracy.crooks@reckittbenckiser.com)

### Advisory Panel

Elliot Brown

Managing Director, Elliot Brown Consulting Ltd

David Cousins

Head of Safe Medication Practice, National Patient Safety Agency

Alison Ewing

Clinical Director of Pharmacy, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Graeme Ladds

Director, PharSafer Associates Ltd.

Sunayana Shah

Scientific & Medical Affairs Manager at the Proprietary Association of Great Britain (PAGB)

### Publisher

Joe Ridge

### Design & Production

Sarah Beale

### Subscriptions

Jill Monk

email: [subs@euromedcommunications.com](mailto:subs@euromedcommunications.com)

Published by Euromed Communications Ltd  
Passfield Business Centre, Passfield, Liphook,  
Hampshire GU30 7SB, UK  
Tel: +44 (0)1428 752222  
Fax: +44 (0)1428 752223

email: [info@euromedcommunications.com](mailto:info@euromedcommunications.com)  
[www.euromedcommunications.com](http://www.euromedcommunications.com)

Euromed Communications Ltd also publish  
Clinical Research Manual; Paediatric Clinical  
Research Manual, Medical Devices Manual and  
Compendium of Quality of Life Instruments

Copyright: No part of this journal may be reproduced without written permission from the Publishers. The comments of the contributors are their own and are not necessarily endorsed by the Publisher, Editor or Advisory Panel. Accordingly the Publisher, Editor or Advisory Panel accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement. The Editor's decision is final and no correspondence will be entered into. The utmost care has been taken to ensure accuracy of detail, but the publishers cannot accept responsibility for errors or omissions.

© 2011 Euromed Communications Ltd

ISSN 1752-6752

# Contents

November 2011 • Volume 5 Number 4

## 3 Editorial comment

Tracy Crooks

## 4 Direct patient ADR reporting: how is it relevant to the pharmaceutical industry?

Despite concerns expressed by health professionals and pharmaceutical companies, direct patient reporting of adverse effects has led to a significant number of relevant and trustworthy reports.

Janet Kraska and Tony Avery

## 8 The impact of electronic prescribing on adverse drug events and medication risk

Using computer systems has been shown to reduce medication errors and improve reporting of adverse events.

Stephen Goundrey-Smith

## 11 Systems biology and drug regulation

New scientific discoveries in genomics, imaging and bioinformatics can increase the accuracy of tests to improve the safety and efficacy of drugs in development, particularly paediatric drugs and drug combinations.

Judith Farrés, Juan Bigorra and Jordi Naval

## 13 De-identification of electronic health records for genomic research

De-identification of data is a means of facilitating disclosure of genomic data to researchers. The author describes and analyses the various methods.

Khaled El Emam

## 19 Practical considerations for preparing Development Safety Update Reports (DSUR)

The authors provide practical guidance to help companies produce periodic reports useful to Sponsors, Regulators and Ethics Committees.

Sue Rees and Stewart Geary